Lalan Wilfong, MD, executive vice president, Value Based Care & Quality Programs, Texas Oncology, and co-chair, Payment Reform, Community Oncology Alliance, discusses implications of quality metrics in cancer care and what perspectives on the topic he is looking forward to hearing at the 2021 Community Oncology Conference.
Lalan Wilfong, MD, is the executive vice president of Value Based Care & Quality Programs at Texas Oncology and Payment Reform Co-Chair at the Community Oncology Alliance.
Transcript
For the 2021 Community Oncology Conference, a panel will discuss quality measurement in cancer care. How has use of quality metrics influenced the way in which cancer care has been delivered and perceived in recent years?
Quality metrics have influenced the way that we measure and perceive cancer care by focusing us more on what means most to patients, and how do we improve the outcomes that we provide versus just managing patients as best we see.
Things like metrics in the Oncology Care Model for reducing hospitalizations and reducing ED [emergency department] visits makes us think through the entire patient care continuum versus focusing on just what's happening that day with a patient.
So, it has led to significant changes in the way that we think and deliver cancer care. That being said, I am looking forward to the session on quality measures because we need to think through better how we reduce the burden on reporting from practices, which is a significant issue for reporting quality metrics, while at the same time really focusing on those that impact outcomes the most.
What perspectives are you looking forward to hearing during the panel discussion?
I think for my panel discussion, we're going to talk about the new model for cancer care, and one of the things we're going to discuss is how it needs to be flexible. Different practices, different payers, patient populations need different focus to continue to improve the value we provide them.
Some practices are very sophisticated, some payers are sophisticated—some are not. So, how do you get everybody moving forward? And that's one of the things that we will discuss is the flexibility needed for us all to get there, because there's not going to be a one-size fits all model that we can take forward. So I'm really looking forward to discussing that and hearing opinions on that process.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age
March 28th 2024A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More